By David Armstrong, Annie Waldman and Daniel GoldenProPublica ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox. On the fourth floor of the University of Florida…
A huge proportion of medical research is funded by industry even though studies show company-sponsored studies tend to overstate benefits, playdown harms.
Not all research is good. Not all headlines reflect what a study found. So how can you tell if a story about news about medical research is bogus or legit?
Neuroscientists have created interactive maps that can predict where different categories of words activate the brain
In 2004, Californians voted to shell out billions in taxpayer money to fund stem cell research. But 15 years later, some are asking ‘Where are the cures?”
Human-animal hybrids are coming and could be used to grow organs for transplant. What does it mean? A philosopher weighs in
“We hope to attract the best and brightest in the world to the institute to work on what we believe is going to be a protein-design revolution.”
The researcher making these claims has a considerable financial stake in his claims being proven correct.
How can doctors work out what treatments actually work? Here’s where a type of study called a clinical trial is useful.
Industry-sponsored research tends to be more positive than that financed by other sources, that in turn can sway which treatments become available to patients
Top researchers at Memorial Sloan Kettering Cancer Center have filed at least six corrections with medical journals recently, divulging financial relationships with health care companies that they did not previously disclose.
Every surface of our body – inside and out – is covered in microorganisms: bacteria, viruses, fungi and many other microscopic life forms.
The Trump administration faces mounting pressure from conservative lawmakers and abortion opponents to halt the use of tissue obtained from aborted fetuses.
Black people and Native Americans are under-represented in clinical trials, even when the drugs are aimed at a cancer that disproportionately affects them.